DNA vaccines that expresses mutant ADP-ribosyltransferase toxins which display reduced, or are devoid of, ADP-ribosyltransferase activity
OwnerDavid Honeinventor
Life of this patent
Estimating the term…
Abstract
The present invention provides DNA vaccines that direct the coincident expression of vaccine antigens coincidently with mutant ADP-ribosyltransferase toxins (mARTs), which display reduced, or are devoid of, ADP-ribosyltransferase activity, and methods for vaccinating animals with the same. In particular, the present invention provides DNA vaccines that direct the coincident expression of vaccine antigens and mARTs that are useful for vaccinating against viral, bacterial, parasitic pathogens, autoimmune antigens and transplantation antigens.
Claims20
A DNA vaccine, comprising:
- at least one genetic sequence encoding a mutant ADP-ribosyltransferase toxin (mART);
- and
- at least one genetic sequence encoding an antigen.
A vaccine composition, comprising:
- an antigen;
- and
- at least one genetic sequence encoding a mutant ADP-ribosyltransferase toxin (mART).
A vaccine composition, comprising:
- a DNA vaccine that expresses an antigen;
- and
- at least one genetic sequence encoding a mutant ADP-ribosyltransferase toxin (mART).
A method of vaccinating a patient, comprising:
- introducing into said patient at least one genetic sequence encoding a mutant ADP-ribosyltransferase toxin (mART) and at least one genetic sequence encoding an antigen;
- expressing said mART and said antigen after said introducing step.
Dependencies are inferred from the claim text.